A once-weekly GLP-1 RA

A once-weekly GLP-1 RA

In addition to standard of care in patients with T2DM and at high risk of CV events,

Ozempic® demonstrated a CV outcome (MACE) safety endpoint at 2 years1,20*

Contribution of each MACE component to the primary composite endpoint

No increased risk for MACE was observed with Ozempic®.

* Adapted from Marso SP et al., 2016.20
† Standard of care included oral antihyperglycemic treatments, insulin, antihypertensives, diuretics, antithrombotic and lipid-lowering therapies.20
CI, confidence interval; CV, cardiovascular; HR, hazard ratio; MACE, major adverse cardiovascular event; MI, myocardial infarction; SOC, standard of care.

Contact Us

Novo Nordisk would like every healthcare practitioner to be able to obtain information as easily and quickly as possible.
If you need information about Ozempic®, please contact:

Novo Nordisk Canada Inc.
101-2476 Argentia Road
Mississauga, Ontario
L5N 6M1

Business hours are:
Monday to Friday from
8:30 a.m. to 5:00 p.m. EST

Main number:

Main fax number:
Toll-free fax number: